Antioxidant and anti-inflammatory effects of intravenously injected adipose derived mesenchymal stem cells in dogs with acute spinal cord injury

Stem Cell Research & Therapy

Oh-Kyeong Kweon¹  Wan Hee Kim¹  Sung-ho Jo¹  Yongsun Kim¹ 

[1] BK21 PLUS Program for Creative Veterinary Science Research, Research Institute for Veterinary Science and College of Veterinary Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, South Korea

关键词: Dog;    Mesenchymal stem cells;    Spinal cord injury;    Anti-inflammatory;    Antioxidant;   

Others  :  1235099
DOI  :  10.1186/s13287-015-0236-5

 received in 2015-04-30, accepted in 2015-11-10,  发布年份 2015

【 摘 要 】

Introduction

Mesenchymal stem cells can potentially be used in therapy for spinal cord injury (SCI). Methylprednisolone sodium succinate (MPSS) has been used as a scavenging agent in acute SCI treatment, but its use no longer recommended. This study aimed to identify ways to reduce the usage and risk of high doses of glucocorticoid steroids, and determine whether AD-MSCs could be used as an early alternative treatment modality for acute SCI.

Methods

Sixteen adult beagle dogs with SCI were assigned to four treatment groups: control, MPSS, AD-MSCs, and AD-MSCs + MPSS. Additionally, one dog was used to evaluate the distribution of AD-MSCs in the body after injection. AD-MSCs (1 × 10 ⁷cells) were injected intravenously once a day for 3 days beginning at 6 hours post-SCI. MPSS was also injected intravenously according to the standard protocol for acute SCI. A revised Tarlov scale was used to evaluate hindlimb functional recovery. The levels of markers for oxidative metabolism (3-nitrotyrosine, 4-hydroxynonenal, and protein carbonyl) and inflammation (cyclooxygenase-2, interleukin-6, and tumor necrosis factor-α) were also measured.

Results

At 7 days post-treatment, hindlimb movement had improved in the AD-MSCs and AD-MSCs + MPSS groups; however, subjects in the groups treated with MPSS exhibited gastrointestinal hemorrhages. Hematoxylin and eosin staining revealed fewer hemorrhages and lesser microglial infiltration in the AD-MSCs group. The green fluorescent protein-expressing AD-MSCs were clearly detected in the lung, spleen, and injured spinal cord; however, these cells were not detected in the liver and un-injured spinal cord. Levels of 3-nitrotyrosine were decreased in the MPSS and AD-MSCs + MPSS groups; 4-hydroxynenonal and cyclooxygenase-2 levels were decreased in all treatment groups; and interleukin-6, tumor necrosis factor-α, and phosphorylated-signal transducer and activator transcription 3 levels were decreased in the AD-MSCs and AD-MSCs + MPSS groups.

Conclusion

Our results suggest that early intravenous injection of AD-MSCs after acute SCI may prevent further damage through enhancement of antioxidative and anti-inflammatory mechanisms, without inducing adverse effects. Additionally, this treatment could also be used as an alternative intravenous treatment modality for acute SCI.

【 授权许可】

   
2015 Kim et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Oyinbo CA: Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. Acta Neurobiol Exp (Wars) 2011, 71:281-99.
• [2]Wang J, Rogove AD, Tsirka AE, Tsirka SE: Protective role of tuftsin fragment 1–3 in an animal model of intracerebral hemorrhage. Ann Neurol 2003, 54:655-64.
• [3]Wang J, Dore S: Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2007, 27:894-908.
• [4]Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 1989, 320:365-76.
• [5]Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, et al.: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990, 322:1405-11.
• [6]Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, et al.: Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277:1597-604.
• [7]Hurlbert RJ: Methylprednisolone for the treatment of acute spinal cord injury: point. Neurosurgery 2014, 61(Suppl 1):32-5.
• [8]Molano Mdel R, Broton JG, Bean JA, Calancie B: Complications associated with the prophylactic use of methylprednisolone during surgical stabilization after spinal cord injury. J Neurosurg 2002, 96:267-72.
• [9]Park SS, Byeon YE, Ryu HH, Kang BJ, Kim Y, Kim WH, et al.: Comparison of canine umbilical cord blood-derived mesenchymal stem cell transplantation times: involvement of astrogliosis, inflammation, intracellular actin cytoskeleton pathways, and neurotrophin-3. Cell Transplant 2011, 20:1867-80.
• [10]Lim JH, Byeon YE, Ryu HH, Jeong YH, Lee YW, Kim WH, et al.: Transplantation of canine umbilical cord blood-derived mesenchymal stem cells in experimentally induced spinal cord injured dogs. J Vet Sci 2007, 8:275-82.
• [11]Ryu HH, Lim JH, Byeon YE, Park JR, Seo MS, Lee YW, et al.: Functional recovery and neural differentiation after transplantation of allogenic adipose-derived stem cells in a canine model of acute spinal cord injury. J Vet Sci 2009, 10:273-84.
• [12]Rabinowitz RS, Eck JC, Harper CM Jr, Larson DR, Jimenez MA, Parisi JE, et al.: Urgent surgical decompression compared to methylprednisolone for the treatment of acute spinal cord injury: a randomized prospective study in beagle dogs. Spine 2008, 33:2260-8.
• [13]Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-54.
• [14]Perrone MG, Scilimati A, Simone L, Vitale P: Selective COX-1 inhibition: a therapeutic target to be reconsidered. Curr Med Chem 2010, 17:3769-805.
• [15]Khan MF, Burks SS, Al-Khayat H, Levi AD: The effect of steroids on the incidence of gastrointestinal hemorrhage after spinal cord injury: a case-controlled study. Spinal Cord 2014, 52:58-60.
• [16]Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2014;4:e004587. doi:. 10.1136/bmjopen-2013-004587 webcite
• [17]Hall ED: Antioxidant therapies for acute spinal cord injury. Neurotherapeutics 2011, 8:152-67.
• [18]Lanza C, Morando S, Voci A, Canesi L, Principato MC, Serpero LD, et al.: Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem 2009, 110:1674-84.
• [19]Hall ED, Springer JE: Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 2004, 1:80-100.
• [20]Seo JH, Jang IK, Kim H, Yang MS, Lee JE, Kim HE, et al.: Early immunomodulation by intravenously transplanted mesenchymal stem cells promotes functional recovery in spinal cord injured rats. Cell Med 2011, 2:55-67.
• [21]Hoogduijn MJ, Popp F, Verbeek R, Masoodi M, Nicolaou A, Baan C, et al.: The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int Immunopharmacol 2010, 10:1496-500.
• [22]Jui HY, Lin CH, Hsu WT, Liu YR, Hsu RB, Chiang BL, et al.: Autologous mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin-10, interferon-gamma, and indoleamine 2,3-dioxygenase. Cell Transplant 2012, 21:971-84.
• [23]Dominguez E, Rivat C, Pommier B, Mauborgne A, Pohl M: JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat. J Neurochem 2008, 107:50-60.
• [24]Nakamura M, Okada S, Toyama Y, Okano H: Role of IL-6 in spinal cord injury in a mouse model. Clin Rev Allergy Immunol 2005, 28:197-204.
• [25]Lukovic D, Stojkovic M, Moreno-Manzano V, Jendelova P, Sykova E, Bhattacharya SS, et al.: Concise review: reactive astrocytes and stem cells in spinal cord injury: good guys or bad guys? Stem Cells 2015, 33:1036-41.
• [26]Burda JE, Bernstein AM, Sofroniew MV. Astrocyte roles in traumatic brain injury. Exp Neurol. 2015; doi:. 10.1016/j.expneurol.2015.03.020 webcite
• [27]Sykova E, Jendelova P: Migration, fate and in vivo imaging of adult stem cells in the CNS. Cell Death Differ 2007, 14:1336-42.
• [28]Takahashi Y, Tsuji O, Kumagai G, Hara CM, Okano HJ, Miyawaki A, et al.: Comparative study of methods for administering neural stem/progenitor cells to treat spinal cord injury in mice. Cell Transplant 2011, 20:727-39.
• [29]Okazaki T, Magaki T, Takeda M, Kajiwara Y, Hanaya R, Sugiyama K, et al.: Intravenous administration of bone marrow stromal cells increases survivin and Bcl-2 protein expression and improves sensorimotor function following ischemia in rats. Neurosci Lett 2008, 430:109-14.
• [30]Wang SP, Wang ZH, Peng DY, Li SM, Wang H, Wang XH: Therapeutic effect of mesenchymal stem cells in rats with intracerebral hemorrhage: reduced apoptosis and enhanced neuroprotection. Mol Med Rep 2012, 6:848-54.
• [31]Kim HJ, Lee JH, Kim SH: Therapeutic effects of human mesenchymal stem cells on traumatic brain injury in rats: secretion of neurotrophic factors and inhibition of apoptosis. J Neurotrauma 2010, 27:131-8.
• [32]Ben-Hur T: Immunomodulation by neural stem cells. J Neurol Sci 2008, 265:102-4.
• [33]Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al.: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-61.